PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Lazertinib royalties and three consecutive out-licensing deals have pushed Oscotec into profit, yet lumpy one-off milestone income and the unresolved buyout of Genosco remain side by side.
In 2025 consolidated revenue was KRW 99.8bn with operating profit of KRW 52.1bn (52.2% margin), a swing into the black, and the first half of 2026 delivered revenue of KRW 56.3bn and operating profit of KRW 28.7bn.
Profits cluster around milestone recognition: operating profit was KRW 61.4bn in Q4 2025 and KRW 38.7bn in Q2 2026, while Q1 2026 posted a KRW 10.0bn operating loss.
Lazertinib economics are split 60% Yuhan, 20% Oscotec and 20% Genosco, so 40% flows into consolidated results.
Out-licensing continued with Sanofi (ADEL-Y01) in December 2025 and Agios (cevidoplenib) in June 2026; the USD 25m cevidoplenib upfront was booked in Q2 2026.
The authorized-share increase needed to fund the purchase of the remaining Genosco stake was voted down at the December 2025 EGM and remains unresolved.
Oscotec is a small-molecule drug developer founded in 1998 whose model is to out-license assets at the clinical stage. Its US subsidiary Genosco is the core R&D base, and Oscotec holds a 59.3% stake in Genosco.
The revenue backbone is running royalties on lazertinib, the EGFR-mutant non-small cell lung cancer drug transferred to Yuhan Corporation at the preclinical stage in 2015.
Yuhan sub-licensed global rights to Johnson & Johnson in 2018, and Oscotec and Genosco each receive 20% of Yuhan's technology income, so 40% is captured on a consolidated basis.
On top of that, the Alzheimer's antibody candidate ADEL-Y01 was licensed to Sanofi in December 2025 for up to USD 1.04bn, and the autoimmune candidate cevidoplenib to Agios in June 2026 for up to USD 665m, giving three global licensing deals.
The Agios contract comprises a USD 25m upfront plus up to USD 640m in development and commercial milestones, with proceeds split 75% Oscotec and 25% Genosco. By segment, 97.3% of first-half 2026 revenue came from the drug development business.
The in-house pipeline has been reshaped around OCT-598, an EP2/EP4 dual inhibitor in-licensed from Kanaph Therapeutics in 2022 and now in a domestic Phase 1a with Korea-US Phase 1b in preparation, and OCT-648, a NUAK1 inhibitor program for kidney fibrosis with candidate selection targeted for the second half, plus Genosco's idiopathic pulmonary fibrosis candidate GNS-3545, a ROCK2 inhibitor in global Phase 1.
Because the model earns royalties without an owned sales network, results hinge simultaneously on standard-of-care competition in the end market and on the pace of follow-on licensing.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩10B | -₩600M | −6.3% |
| 2025Q3 | ₩8.9B | -₩400M | −4.2% |
| 2025Q4 | ₩78.9B | ₩61.4B | 77.8% |
| 2026Q1 | ₩3.6B | -₩10B | −273.8% |
| 2026Q2 | ₩52.6B | ₩38.7B | 73.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩5.1B | -₩28.6B | -₩24.4B | −565.7% | −19.9% | 18.0% |
| 2023 | ₩5B | -₩32.7B | -₩24.3B | −659.6% | −24.5% | 40.0% |
| 2024 | ₩34B | -₩2.7B | ₩900M | −8.0% | 0.7% | 29.0% |
| 2025 | ₩99.8B | ₩52.1B | ₩52.3B | 52.2% | 28.9% | 23.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
On confirmed figures, 2025 consolidated revenue was KRW 99.8bn with operating profit of KRW 52.1bn and net profit attributable to owners of KRW 52.3bn, an operating margin of 52.2%.
That marks a swing from operating losses of KRW 2.7bn in 2024, KRW 32.7bn in 2023 and KRW 28.6bn in 2022, while revenue expanded sharply from KRW 5.0bn in 2023 and KRW 34.0bn in 2024. The quarterly path shows how concentrated the earnings are.
Against revenue of KRW 10.0bn and a KRW 0.6bn operating loss in Q2 2025, and KRW 8.9bn revenue with a KRW 0.4bn loss in Q3 2025, Q4 2025 alone produced revenue of KRW 78.9bn and operating profit of KRW 61.4bn.
The same pattern repeated in 2026: Q1 revenue was KRW 3.6bn with a KRW 10.0bn operating loss as first-quarter R&D spending reached KRW 6.35bn, before Q2 flipped to revenue of KRW 52.6bn, operating profit of KRW 38.7bn and owners' net profit of KRW 36.7bn, helped by USD 10.2m on a consolidated basis from the lazertinib European commercialization milestone and the USD 25m Agios upfront received on June 17 and booked in the second quarter.
First-half revenue therefore totalled KRW 56.3bn with operating profit of KRW 28.7bn, while first-half R&D expense rose 20.6% year on year to KRW 15.04bn. Because licensing income carries little cost of sales, margins spike in recognition quarters and revert to losses in quarters without them.
On cash, 2025 operating cash flow of positive KRW 8.3bn broke the outflow streak of negative KRW 26.0bn in 2024, negative KRW 22.0bn in 2023 and negative KRW 26.4bn in 2022, yet the gap versus KRW 52.1bn of operating profit highlights the timing difference between accounting recognition and cash receipt.
The balance sheet ended 2025 with total equity of KRW 186.8bn (KRW 181.3bn attributable to owners), total liabilities of KRW 43.0bn and a debt-to-equity ratio of 23.0%, indicating low leverage.
In the end market, first-line therapy for EGFR-mutant non-small cell lung cancer is a three-way contest: AstraZeneca's Tagrisso monotherapy, Tagrisso plus chemotherapy, and Rybrevant plus Lazcluze are all listed in the NCCN guidelines.
The lazertinib-amivantamab combination is recommended as a Category 1 preferred regimen in the NCCN guidelines, placing it alongside existing standards of care as a major first-line option.
Prescription momentum is visible in reported sales: second-quarter 2026 global sales of the combination reached USD 289m, up 60.8% year on year and 12.5% quarter on quarter, with US sales of USD 190m (+36.8%) and ex-US sales of USD 99m, up 141.5%.
Approval and reimbursement coverage has widened to Europe, Japan, Canada, Australia and China, driving faster growth outside the US. On convenience, the subcutaneous Rybrevant formulation has been covered by a US reimbursement J-code since July 2026, simplifying claims.
Within Korea's drug development sector, Oscotec sits in the small group of names that collect sales royalties before their own clinical outcomes are known, and one independent research house pointed to its cash holdings and low leverage as evidence it can fund in-house trials without external financing.
That said, a royalty-based model leaves results structurally dependent on the partner's commercial strategy and on competing clinical datasets.
Management's stated direction is to recycle licensing proceeds into follow-on programs.
At a June 2026 briefing, CEO Yoon Tae-young said the next two to three years would center on the anti-resistance oncology asset OCT-598 and the fibrosis program OCT-648, and presented a 'Roadmap to 2030' targeting two additional preclinical candidates and at least two further out-licensing deals in 2027-2028.
OCT-598 is in a domestic Phase 1a with Korea-US Phase 1b in preparation, while OCT-648 is slated for final candidate selection in the second half of 2026.
Further cash from licensed assets depends on partner progress; brokerages expect Agios to enter a Phase 3 in ITP in the first half of 2028 after the formulation-change study completes.
On lazertinib, IBK Investment & Securities forecast in an August 2026 report that related royalty income would grow from KRW 15.6bn in 2026 to KRW 88.8bn in 2028, while the same report projected 2026 revenue of KRW 75.1bn and operating profit of KRW 22.4bn, down 24.8% and 57.0% respectively from 2025, attributing the decline to the base effect of the large upfront and commercialization milestones booked in 2025.
On the data calendar, Eugene Investment & Securities said in an April 2026 report that median overall survival for the combination should be confirmed in the second half, with the industry expecting the final figure to be disclosed at major conferences.
On governance, the authorized-share increase that is central to the Genosco buyout was rejected at the December 2025 EGM and was not tabled at the 2026 annual meeting, leaving the funding route unclear.
Earnings from 2026 onward will therefore likely be set by the pace of recurring royalty growth, the timing of irregular milestone recognition, and the trajectory of R&D spending.
A large share of Oscotec's profit comes from irregular items such as upfronts and stage milestones, so a price-earnings multiple computed from the last four quarters of net profit shifts materially depending on whether a milestone-heavy quarter sits inside the window.
Quarters without licensing recognition, such as Q1 2026, produce operating losses, so stringing together the same multiple quarter by quarter can swing widely.
Relative to net assets the shares trade at a premium, consistent with how KOSDAQ drug developers are generally valued on pipeline potential rather than current book.
No cash dividend is paid, so there is no dividend yield, and the company has said the upfront will be deployed into R&D including the anti-resistance oncology program and OCT-648.
As for street targets, IBK Investment & Securities presented KRW 67,000 in an August 2026 report, and Eugene Investment & Securities presented KRW 75,000 in an April 2026 report.
Separately, whether the remaining Genosco stake is brought in-house changes how much of the same pipeline outcome accrues to Oscotec shareholders, which belongs in any valuation discussion.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Global sales of the lazertinib-amivantamab combination reached USD 289m in Q2 2026, up 60.8% year on year and a quarterly record. Ex-US sales jumped 141.5% to USD 99m, growing faster than the US. Analysis of the partner's results also noted the shift from one-off milestones toward sales-linked royalties.
Since 40% of Yuhan's technology income is captured on consolidation, prescription growth feeds directly into Oscotec's top line.
Shinhan Investment analysts described the June 2026 Agios contract as the third global licensing deal after lazertinib and ADEL-Y01, saying it demonstrated R&D capability to out-license across oncology, CNS and immunology.
The company noted that its legacy pipeline, including lazertinib, denfivontinib and cevidoplenib, has now all been licensed out. That record shows the discovery-and-early-clinical model has worked repeatedly. Whether it repeats again must still be validated by data on the next set of assets.
At end-2025 total equity was KRW 186.8bn against liabilities of KRW 43.0bn for a debt-to-equity ratio of 23.0%, and 2025 operating cash flow turned positive at KRW 8.3bn. Press reports in June 2026 said the company held KRW 158.5bn of liquidity when the cevidoplenib upfront arrived on top.
Growth Research wrote in a May 2026 field report that Oscotec has the financial capacity to run its own trials and follow-on research without external funding. The recurring equity-raise burden typical of biotech is, for now, reduced.
Operating profit was KRW 61.4bn in Q4 2025 and KRW 38.7bn in Q2 2026, versus a KRW 10.0bn operating loss in Q1 2026, an unusually wide quarterly swing. Most of the KRW 52.1bn of 2025 operating profit was likewise concentrated in the fourth quarter.
IBK Investment & Securities forecast in an August 2026 report that 2026 revenue and operating profit would fall 24.8% and 57.0% respectively, citing the base effect of the large 2025 upfront and milestones. Whether recurring royalties alone can absorb fixed costs is something to check quarter by quarter.
The plan to make Genosco a wholly owned subsidiary collapsed when the articles-amendment and related items were voted down at the December 2025 extraordinary general meeting.
Management proposed funding the remaining stake through a third-party share placement, but only about 1.74m shares remain issuable under the articles, and the proposal to lift authorized shares from 40m to 50m was rejected.
Views on Genosco's value have also diverged sharply between Oscotec shareholders and Genosco shareholders, at roughly KRW 700bn versus over KRW 1trn. While the buyout is delayed, part of any pipeline success continues to accrue to non-controlling interests.
Of the KRW 37.5bn cevidoplenib upfront, about KRW 28.1bn accrues to Oscotec, and even full receipt of the headline contract value would leave Oscotec with roughly KRW 750bn, a maximum that presumes success at every stage.
Commentators also noted that up to USD 640m of milestones cannot be treated as present income, that the contract can terminate if trials, approval or commercialization do not materialize, and that the observable markers narrow to Agios entering Phase 3, indication expansion and post-launch sales.
Cevidoplenib missed the primary endpoint in its ITP Phase 2, with the company saying durable platelet responses were seen in secondary endpoints. The follow-on pipeline also remains at early clinical stages.
The in-house pipeline is concentrated in early stages. OCT-598 is in a domestic Phase 1a with Korea-US Phase 1b in preparation, and OCT-648 is at the final candidate-selection stage.
In a regulatory filing the company noted that the statistical probability of a trial drug reaching final approval is around 10%, and that commercialization plans may change if results fall short. Any stage failure changes both the timing and the size of milestone inflows.
A shareholder coalition won at first instance in its suit challenging the supermajority clause, Oscotec appealed and the case is at the second instance; observers noted the appeal outcome could retroactively unsettle the legitimacy of elected directors and that the litigation may drag on.
The controlling family's inheritance tax burden has been flagged as a medium-term supply variable, and after the succession process concluded in July 2026 the combined stake on the largest-shareholder side was set at 12.45%. If large-scale funding for the Genosco buyout is revived, the debate over new share issuance could resurface.
The lazertinib combination competes inside the first-line guidelines against Tagrisso monotherapy and Tagrisso plus chemotherapy, and new targeted and antibody-drug conjugate entrants continue to arrive. Because royalties track partner sales, prescription share and the pace of reimbursement by region drive results.
In addition, a company official referred to past tax issues around lazertinib and said the tax impact of this upfront would only be clear in the half-year report, so gaps between revenue and net profit can appear quarter to quarter. With receipts denominated in dollars, currency moves also affect recognized amounts.
Watch Johnson & Johnson's third-quarter results for the sales trajectory of the Rybrevant-Lazcluze combination. Whether the subcutaneous formulation's US J-code, effective from July 2026, shows up in prescriptions and sales is a leading indicator for Oscotec's recurring royalties.
Check whether final median overall survival data for the combination are disclosed at second-half conferences such as ESMO. Whether the survival gain versus the competing regimen is confirmed in official data is a variable for first-line prescribing.
In the third-quarter report, look at recurring royalty revenue excluding one-off upfronts alongside the pace of R&D spending. Whether the 20.6% year-on-year increase in first-half R&D expense continues will shape the direction of quarterly profit.
Progress markers include final candidate selection for OCT-648 and the start of the Korea-US Phase 1b for OCT-598. These are preconditions for the company's stated goal of at least two more out-licensing deals in 2027-2028.
The key question is whether items tied to the Genosco buyout, including an authorized-share increase, are tabled again. The parallel appeal ruling on the supermajority clause could also affect board composition and the odds of resolutions passing.
Oscotec's earnings moved out of the 2022-2024 loss phase into revenue of KRW 99.8bn and operating profit of KRW 52.1bn in 2025, followed by KRW 56.3bn of revenue and KRW 28.7bn of operating profit in the first half of 2026.
That profit, however, clusters in quarters when upfronts and milestones are recognized, such as KRW 61.4bn of operating profit in Q4 2025 and KRW 38.7bn in Q2 2026, while Q1 2026 showed a KRW 10.0bn operating loss.
On the facts, the supportive side includes the combination's Q2 2026 global sales of USD 289m, up 60.8% year on year, with ex-US sales up 141.5%, plus the funding secured from three global licensing deals.
The cautionary side includes the base effect of the large 2025 upfront and milestones, uncertainty over recognizing conditional milestones, and the unclear funding route for making Genosco a wholly owned subsidiary.
The balance sheet is lightly levered with a 23.0% debt-to-equity ratio at end-2025 and operating cash flow has turned positive, but the timing gap between accounting recognition and cash receipt remains worth monitoring.
What matters from here is how fast recurring royalties absorb rising R&D costs, how the follow-on pipeline advances clinically, and which direction the governance cleanup takes. This material is for information purposes only and contains no buy or sell recommendation or price target.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.